

2 July 2025

## VITASORA RAISES \$11M FOLLOWING STRONG SUPPORT FROM INSTITUTIONAL AND LONG TERM SHAREHOLDERS

### Highlights

- Vitasora raises \$11 million, following strong support from institutional and long term shareholders.
- Funds will support the Company through to cash flow breakeven in H2 FY2026, providing working capital to fund rapid growth.
- Strong investor support reflects confidence in Vitasora's ability to deliver at scale, following the timely execution of the TPAC Agreement and continued expansion of programs with existing clients.
- CEO and Chairman committed to participate for a total of \$500,000, subject to shareholder approval.

**Vitasora Health** Limited (ASX:VHL; OTCQB:VHLUF) ("Vitasora" or "the Company"), formerly known as Respire Limited (ASX:RSH; OTCQB:RSHUF), a leader in the delivery of AI-powered, Connected Care solutions in the U.S. healthcare market, is pleased to announce that it has received firm commitments to raise approximately \$11 million (before expenses) via a placement to sophisticated, professional and institutional investors ("Placement").

The Placement was well supported, reflecting growing investor confidence in the Company's strategy, execution capability and market opportunity. This included participation from new institutional investors and a key investor contributing approximately \$6.75 million (USD\$4.5 million). The Placement (excluding Director Shares) will comprise the issue of approximately 350 million fully paid ordinary shares at an issue price of \$0.03 per Share, representing a 16.2% discount to the 5-day VWAP of \$0.0358 per Share utilising the Company's Placement capacity.

A total of 194 million Shares in accordance with the Company's Placement capacity under ASX Listing Rule 7.1 and 156 million Shares in accordance with the Company's Placement capacity under ASX Listing Rule 7.1A.

The net proceeds of the Placement will be used to fund:

- Expanded clinical operations and program delivery
- Technology platform enhancements and client system integration
- Client Key Account Management
- Sales, business development, and marketing
- Regulatory and compliance
- Working capital and offer-related costs

This capital raise ensures that Vitasora is fully funded through to cash flow breakeven in H2 FY2026, supporting the Company's continued growth and commercial rollout across its client base.

Commenting on the outcome of the Placement, Marjan Mikel, CEO of Vitasora, said:

*"We are very pleased with the outcome of this raise, which exceeded our original target and attracted strong support from high-quality institutional and long term shareholders. This result reflects confidence in our delivery, particularly following the successful execution of the expanded Value-based TPAC partnership. We're building a scalable, high-performance business with measurable impact—and now we're funded to see that through."*

## Investor Outlook

Investor demand was underpinned by Vitasora's consistent delivery across all aspects of operational execution, reinforcing confidence in the Company's ability to meet its commitments reliably and at scale.

Key drivers included:

- Successful, on-time execution of the TPAC agreement, which exceeded client expectations and led to its expansion into a value-based care agreement
- Broader expansion of contracted scope with other existing clients
- Strengthening of strategic client relationships across the portfolio
- Acceleration of the near-term sales pipeline, including multiple high-value opportunities

The success of this capital raise reflects strong market endorsement of Vitasora's execution capability, strategic positioning, and near-term growth potential. With additional commercial 'wins' anticipated in H2 CY 2025 and continued momentum from expanding value-based agreements, the Company is well positioned to scale efficiently, deliver measurable outcomes, and generate long-term shareholder value.

## Director Participation

Marjan Mikel (CEO) and Nicholas Smedley (Chairman) have committed to participate for a combined total of \$500,000 under the Placement. The issue of 16.67 million shares to directors will be subject to shareholder approval at the Company's next extraordinary general meeting (EGM).

## Advisors

Bell Potter Securities Limited and MST Financial Services Pty Ltd acted as Joint Lead Managers (JLMs) to the Placement.

An Appendix 3B for the Placement will be lodged on ASX today.

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Vitasora Health Limited  
P: +61 408 462 873  
E: [marjan@vitasorahealth.com](mailto:marjan@vitasorahealth.com)

**Mr Nicholas Smedley**  
Non-Executive Chairman  
Vitasora Health Limited  
P: +61 447 074 160  
E: [nicholas@vitasorahealth.com](mailto:nicholas@vitasorahealth.com)

*This ASX announcement has been authorised for release by the Board of Directors of Vitasora Health Limited.*

### About Vitasora Health Limited – A Revolutionary Remote Healthcare Solutions Provider

Vitasora Health Limited (ASX:VHL, OTCQB:VHLUF) is redefining digital Connected Care in the U.S. healthcare market. We combine cutting-edge technologies and expert clinical teams to deliver a turnkey solution for providers. Our remote patient monitoring (RPM) and chronic care management (CCM) services improve outcomes, reduce costs, and help healthcare clients thrive in a value-based world. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Connected Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.vitasorahealth.com.au](http://www.vitasorahealth.com.au)

### About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Vitasora, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respi™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respi.co/us/> or for [wheezo®](#)

Vitasora Health Limited is headquartered in Melbourne with offices in Los Angeles.

wheezo® is a registered trademark of Vitasora Health Limited

### Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vitasora's current expectations, estimates and projections about the industry in which Vitasora operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vitasora, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Vitasora cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vitasora only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Vitasora will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.